Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study - PubMed (original) (raw)
Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study
Irena Nulman et al. Am J Psychiatry. 2002 Nov.
Abstract
Objective: Previous work suggested that first-trimester exposure to tricyclic antidepressants or fluoxetine does not affect adversely child IQ and language development. However, many women need antidepressants throughout pregnancy to avoid morbidity and suicide attempts. Little is known about the fetal safety of tricyclic antidepressants and fluoxetine when taken throughout pregnancy. The goal of this study was to assess the effects of tricyclic antidepressants and fluoxetine used throughout gestation on child IQ, language, and behavior.
Method: In a prospective study, mother-child pairs exposed throughout gestation to tricyclic antidepressants (N=46) or fluoxetine (N=40) and an unexposed, not depressed comparison group (N=36) were blindly assessed. The three groups were compared in terms of the children's IQ, language, behavior, and temperament between ages 15 and 71 months. The authors adjusted for independent variables such as duration and severity of maternal depression, duration of pharmacological treatment, number of depression episodes after delivery, maternal IQ, socioeconomic status, cigarette smoking, and alcohol use.
Results: Neither tricyclic antidepressants nor fluoxetine adversely affected the child's global IQ, language development, or behavior. IQ was significantly and negatively associated with duration of depression, whereas language was negatively associated with number of depression episodes after delivery.
Conclusions: Exposure to tricyclic antidepressants or fluoxetine throughout gestation does not appear to adversely affect cognition, language development, or the temperament of preschool and early-school children. In contrast, mothers' depression is associated with less cognitive and language achievement by their children. When needed, adequate antidepressant therapy should be instituted and maintained during pregnancy and postpartum.
Similar articles
- Neurodevelopment of children exposed in utero to antidepressant drugs.
Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, Kulin N, Koren G. Nulman I, et al. N Engl J Med. 1997 Jan 23;336(4):258-62. doi: 10.1056/NEJM199701233360404. N Engl J Med. 1997. PMID: 8995088 - Acute and long-term behavioral outcome of infants and children exposed in utero to either maternal depression or antidepressants: a review of the literature.
Suri R, Lin AS, Cohen LS, Altshuler LL. Suri R, et al. J Clin Psychiatry. 2014 Oct;75(10):e1142-52. doi: 10.4088/JCP.13r08926. J Clin Psychiatry. 2014. PMID: 25373125 Review. - Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study.
Nulman I, Koren G, Rovet J, Barrera M, Streiner DL, Feldman BM. Nulman I, et al. J Clin Psychiatry. 2015 Jul;76(7):e842-7. doi: 10.4088/JCP.14m09240. J Clin Psychiatry. 2015. PMID: 26231010 - Pharmacologic treatment of depression during pregnancy.
Wisner KL, Gelenberg AJ, Leonard H, Zarin D, Frank E. Wisner KL, et al. JAMA. 1999 Oct 6;282(13):1264-9. doi: 10.1001/jama.282.13.1264. JAMA. 1999. PMID: 10517430 Review. - Mother-infant antidepressant concentrations, maternal depression, and perinatal events.
Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL. Sit D, et al. J Clin Psychiatry. 2011 Jul;72(7):994-1001. doi: 10.4088/JCP.10m06461. J Clin Psychiatry. 2011. PMID: 21824458 Free PMC article.
Cited by
- Antidepressant use in pregnancy: a critical review focused on risks and controversies.
Byatt N, Deligiannidis KM, Freeman MP. Byatt N, et al. Acta Psychiatr Scand. 2013 Feb;127(2):94-114. doi: 10.1111/acps.12042. Epub 2012 Dec 14. Acta Psychiatr Scand. 2013. PMID: 23240634 Free PMC article. Review. - Atropinic burden of drugs during pregnancy and psychological development of children: a cohort study in the EFEMERIS database.
Beau AB, Montastruc JL, Lacroix I, Montastruc F, Hurault-Delarue C, Damase-Michel C. Beau AB, et al. Br J Clin Pharmacol. 2016 Aug;82(2):478-86. doi: 10.1111/bcp.12978. Epub 2016 May 29. Br J Clin Pharmacol. 2016. PMID: 27085086 Free PMC article. - Antidepressants use during pregnancy and child psychomotor, cognitive and language development at 2 years of age-Results from the 3D Cohort Study.
Tanguay N, Abdelouahab N, Simard MN, Séguin JR, Marc I, Herba CM, MacLeod AAN, Courtemanche Y, Fraser WD, Muckle G. Tanguay N, et al. Front Pharmacol. 2023 Nov 16;14:1252251. doi: 10.3389/fphar.2023.1252251. eCollection 2023. Front Pharmacol. 2023. PMID: 38035027 Free PMC article. - Prenatal serotonin reuptake inhibitor (SRI) antidepressant exposure and serotonin transporter promoter genotype (SLC6A4) influence executive functions at 6 years of age.
Weikum WM, Brain U, Chau CM, Grunau RE, Boyce WT, Diamond A, Oberlander TF. Weikum WM, et al. Front Cell Neurosci. 2013 Oct 11;7:180. doi: 10.3389/fncel.2013.00180. eCollection 2013. Front Cell Neurosci. 2013. PMID: 24130516 Free PMC article. - Early life programming as a target for prevention of child and adolescent mental disorders.
Lewis AJ, Galbally M, Gannon T, Symeonides C. Lewis AJ, et al. BMC Med. 2014 Feb 24;12:33. doi: 10.1186/1741-7015-12-33. BMC Med. 2014. PMID: 24559477 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical